Connect Biopharma Holdings Limited CNTB

Full chart Compare

Set alert

0.73 USD -0.05 (-6.25%)

At closeNov 5, 2026, 4:00 PM EST

0.73 0.00 0.00%

After hours · Nov 5, 4:00 PM ET

0.71 Day range 0.795

0.71 52-week range 3.82

YTD: -74.05%
1 year: -56.45%

Market cap: 46.08M
Revenue (ttm): 24.12M
Profit margin: -88.66%
EPS (ttm): -1.19
Shares out: 55.25M
Forward P/E: -5.04
YTD return: -74.05%
1-year return: -56.45%

Volume: 432.19K
Avg volume: 3.99M
Open: 0.7731
Previous close: 0.7805
Day's range: 0.71 – 0.795
52-week range: 0.71 – 3.82
Beta: -0.31
Price target: 7.00 (+856.7%)
Earnings date: Mar 30, 2023

1D 5D 1M 3M 6M YTD 1Y 2Y 5Y MAX

Full chart

2Y -0.3990 (-33.81%)

Enterprise value: -57.37M
PEG ratio: 0.00
Price / sales: 2.31
Price / book: 0.50
Dividend yield: 0.00%
Payout ratio: 0.00%
Revenue growth: 0.00%
Free cash flow: -17.08M
Total cash: 110.24M
Total debt: 325.00K
Return on equity: -17.92%
Short % of float: 0.18%
50-day average: 1.12
200-day average: 1.34

Price target (mean) 7.00 +856.7% upside

Now 0.7317

Target (low): 6.00
Target (mean): 7.00
Target (high): 8.00

Ratings (0m) 2 2 buy · 0 hold · 0 sell

Strong buy1
Buy1
Hold0
Sell0
Strong sell0

Mar 30, 2023

Expected Mar 30, 2023. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

CNTB Revenue — quarterly 2.77M

CNTB Net income — quarterly -17.28M

CNTB EPS — quarterly -0.27

CNTB recent earnings
Report date	Quarter ending	EPS estimate	EPS reported	Surprise	Surprise %
Mar 30, 2023	Dec 1, 2022	-0.48	—	—	—

CNTB analyst upgrades and downgrades
Date	Firm	Action	From	To
Sep 6, 2024	HC Wainwright & Co.	reit	Buy	Buy
Jun 13, 2024	HC Wainwright & Co.	reit	Buy	Buy
Apr 17, 2024	HC Wainwright & Co.	main	Buy	Buy
Mar 4, 2024	HC Wainwright & Co.	init	—	Buy
Sep 13, 2023	Cantor Fitzgerald	reit	Overweight	Overweight
Feb 8, 2023	SVB Leerink	main	—	Outperform

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
Country: United States
Website: connectbiopharm.com

News

Your note

CNTB institution ownership
Holder	% held	Shares	Value	Reported
BML Capital Management, LLC	3.79%	2,093,232	2.11M	Sep 29, 2024
O'Connor, A Distinct Business Unit of UBS Asset Mgmt Americas (LLC)	0.92%	510,701	514.48K	Sep 29, 2024
Renaissance Technologies, LLC	0.32%	175,500	176.80K	Sep 29, 2024
Callan Capital LLC	0.08%	41,823	42.13K	Sep 29, 2024
Keudell/Morrison Wealth Management	0.06%	33,450	33.70K	Sep 29, 2024
Royal Bank of Canada	0.06%	30,600	30.83K	Sep 29, 2024

CNTB fund ownership
Holder	% held	Shares	Value	Reported
Fidelity NASDAQ Composite Index Fund	0.05%	27,961	28.17K	Oct 30, 2024

CNTB stock splits
Date	Ratio
May 26, 1998	0.83:1

Connect Biopharma Holdings Limited CNTB

Key statistics

Analyst view

Next earnings

Financials — quick view

Earnings

Upgrades / downgrades

About Connect Biopharma Holdings Limited

News

Your note

Institution ownership

Fund ownership

Splits